Showing 8811-8820 of 9963 results for "".
- North American Facial Injectable Market to Hit $1.7 Billion by 2017https://practicaldermatology.com/news/20121228-north_american_facial_injectable_market_to_hit_17_billion_by_2017/2459652/According to Millennium Research Group, the North American facial injectables market, comprising botulinum toxin and dermal fillers sold in the US and Canada, will continue to show strong growth for the next five years, reaching a total value of more
- AMBI Now Part of Valeant Pharmaceuticalshttps://practicaldermatology.com/news/20121221-ambi_now_part_of_valeant_pharmaceuticals/2459653/Johnson & Johnson has sold the AMBI brand to Valeant Pharmaceuticals North America. Valeant is a multinational, pharmaceutical/OTC company based in Bridgewater, NJ.
- Results Released from Phase 2 Trial of IMO-3100 in Plaque Psoriasishttps://practicaldermatology.com/news/20121219-results_released_from_phase_2_trial_of_imo-3100_in_plaque_psoriasis/2459655/In a recent study, Idera Pharmaceuticals reported that 48 percent of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in
- PreCision Dermatology Adds to Board of Directorshttps://practicaldermatology.com/news/20121211-precision_dermatology_adds_to_board_of_directors/2459660/PreCision Dermatology, Inc. appointed Garen Bohlin to its Board of Directors, effective immediately. Mr. Bohlin has held senior executive posts in leading biotechnology companies for the past 27 years. Most recently, as the Executive Vice Pr
- Valeant, Galderma Revise Agreement Termshttps://practicaldermatology.com/news/20121210-valeant_galderma_revise_agreement_terms/2459661/Valeant Pharmaceuticals International, Inc. reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and co
- Tofacitinib Citrate Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121203-tofacitinib_citrate_approved_for_rheumatoid_arthritis/2459668/Pfizer Inc. received US FDA approval for XELJANZ (tofacitinib citrate) 5mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. XELJANZ
- Jurlique Purely Bright Releases Clinical Resultshttps://practicaldermatology.com/news/20121128-jurlique_purely_bright_releases_clinical_results/2459672/Jurlique Purely Bright, a brightening system launched earlier this year, released clinical results on its product line. After 30 days, the system was clinically proven to help reduce dark spots. After 12 weeks, skin surface smoothness doubled at
- Valeant Receives FTC Clearance For Medicis Acquisitionhttps://practicaldermatology.com/news/20121121-valeant_receives_ftc_clearance_for_medicis_acquisition/2459676/The US Federal Trade Commission (FTC) granted early termination of the waiting period surrounding the proposed acquisition of Medicis Pharmaceutical Corporation by Valeant Pharmaceuticals International, Inc., effective November 15, 2012. The propo
- Xeljanz Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121118-xeljanz_approved_for_rheumatoid_arthritis/2459679/The FDA recently approved Xeljanz (tofacitinib) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to, or who are intolerant of, methotrexate. The decision comes ahead of the product's prescription drug user fee goal date of Nov
- Murad Names Fred Gysi Chief Financial Officerhttps://practicaldermatology.com/news/20121115-murad_names_fred_gysi_chief_financial_officer/2459682/Fred Gysi now serves as Chief Financial Officer for Murad. In this role, Gysi will be responsible for financial reporting, budgeting, treasury and cash flow management, financial and marketing analysis, and strategic planning. Gysi comes to Murad w